Brief: Innate Pharma Presents Data From Ongoing Phase 2 Tellomak Trial Demonstrating Clinical Activity Of Lacutamab In Advanced Sézary Syndrome At Ash 2022
10/12/2022 15:06
Dec 10 (Reuters) - Innate Pharma SA IPH.PA :
* INNATE PHARMA PRESENTS DATA FROM ONGOING PHASE 2 TELLOMAK
TRIAL
DEMONSTRATING CLINICAL ACTIVITY OF LACUTAMAB IN ADVANCED SÉZARY
SYNDROME AT ASH 2022
* INNATE - DEMONSTRATED ENCOURAGING EFFICACY, FAVORABLE
SAFETY
PROFILE IN HEAVILY PRETREATED, POST-MOGAMULIZUMAB PATIENTS WITH
ADVANCED SÉZARY SYNDROME
Source text for Eikon: ID:nBw9YMJ79a
Further company coverage: IPH.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innate Pharma SA
See all newsFrance's Innate Pharma posts lower 2025 revenue as key contracts decline
Brief: Innate Pharma FY Operating Expenses EUR -63.013 Million
Brief: Innate Pharma Sa Says Sanofi to invest up to 15 million Euros In Innate Pharma
Brief: Innate Pharma Says Jonathan Dickinson To Be Appointed CEO And Board Member
French and Benelux stocks-Factors to watch